Integrating Novel Therapies in HFrEF: From Cardiovascular Risk to Survival Benefit

Treating Heart Failure with reduced Ejection Fraction has moved far beyond basic diuresis. This course offers a clear guide to the four pillars of therapy that are currently redefining patient survival. We examine how to transition from traditional blocks to modern, high-impact treatments like ARNIs and SGLT2 inhibitors. You will learn to navigate the practical challenges of initiation and titration while focusing on the long-term goal of reducing cardiovascular death and keeping patients out of the hospital.

By

Prof. Paul. W Armstrong

Current Status

Not Enrolled

Price

Free

Get Started

Treating Heart Failure with reduced Ejection Fraction has moved far beyond basic diuresis. This course offers a clear guide to the four pillars of therapy that are currently redefining patient survival. We examine how to transition from traditional blocks to modern, high-impact treatments like ARNIs and SGLT2 inhibitors. You will learn to navigate the practical challenges of initiation and titration while focusing on the long-term goal of reducing cardiovascular death and keeping patients out of the hospital.

Course Content

Integrating Novel Therapies in HFrEF: From Cardiovascular Risk to Survival Benefit

Presented by

Prof. Paul. W Armstrong

MD

Professor, Department of Medicine (Cardiology), University of Alberta Founding Director, Canadian VIGOUR Centre a University of Alberta Research Centre, Alberta, Canada.